Condition: Hepatocellular Carcinoma Non-resectable · Sponsor: Ze-yang Ding, MD
This study is conducted to evaluate the efficacy, prognosis, adverse effects, and factors for predicting therapeutic effects and clinical prognosis of combined therapy of hepatic artery infusion chemotherapy (HAIC), tyrosine kinase inhibitor/ anti-VEGF antibody, and anti-PD-1/ PD-L1 antibody for advanced hepatocellular carcinoma which initially unsuitable for the radical therapy, including resection, transplantation, or ablation. Factors are collected in preoperative routine blood examination, preoperative radiological imaging and pathological examination.
This description comes directly from the study's public registry record.
ZeYang Ding, M.D. · +86-13407156200 · dingzyang@sina.com
Always discuss trial participation with your own doctor first.
| The Second Affiliated Hospital of Fujian Medical University | Quanzhou, Fujian, China | Recruiting |
| TongjiHospital | Wuhan, Hubei, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05713994